Answers are grounded in this paper and cite their sources.
Analysis assesses donor type effects on transplant outcomes in myelodysplastic syndrome patients, suggesting notable differences in relapse rates.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myelodysplastic neoplasms (MDS). While matched sibling donors (MSD) have traditionally been preferred, the impact of donor type on transplant outcomes under anti-thymocyte globulin (ATG)-based graft-versus-host disease (GVHD) prophylaxis remains unclear. We analyzed 391 adult MDS patients receiving allo-HSCT with fludarabine–busulfan conditioning and ATG between 2009 and 2019. Donors included MSD (n = 155), unrelated donors (UD; n = 134), and haploidentical donors (HID; n = 102). At a median follow-up of 108 months, the 5-year overall survival (OS) and relapse-free survival (RFS) rates were 63.0% and 58.4%. While OS and non-relapse mortality (NRM) did not significantly differ by donor type, MSD recipients had a higher cumulative incidence of relapse compared to UD and HID recipients (34.3% vs. 16.4% and 16.8% at 5 years, p < 0.001), with a trend toward inferior RFS. In multivariate analysis, MSD was independently associated with increased relapse risk and a lower incidence of GVHD, which may reflect a reduced graft-versus-leukemia effect. In this single-center large cohort, MSD transplants were associated with higher relapse risk compared with alternative donors under ATG-based prophylaxis.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: